证券日报网讯华兰疫苗（301207）9月30日在互动平台回答投资者提问时表示，截至2025年9月20日公司 股东为一万七千余户。 ...

Core Viewpoint - The company held its second extraordinary general meeting of shareholders in 2025, where all proposed resolutions were approved without any objections [1][2]. Meeting Details - The meeting took place on September 22, 2025, at 13:30, with both on-site and online voting options available [3][4]. - The total number of shares with voting rights was 595,000,033 [5]. - A total of 152 shareholders participated, representing 487,150,449 shares, which is 81.8740% of the total voting shares [6]. Shareholder Participation - Among the participating shareholders, 150 were small shareholders, representing 28,150,449 shares, or 4.7312% of the total voting shares [7]. - The meeting was presided over by the chairman, Mr. An Kang, and was witnessed by lawyers from Anhui Chengyi Law Firm, who provided a legal opinion confirming the meeting's compliance with regulations [7][8]. Voting Results - The proposal regarding the 2025 mid-term profit distribution plan was approved with 486,923,499 votes in favor, accounting for 99.9534% of the valid votes cast [8]. - Small shareholders voted 27,923,499 shares in favor, representing 99.1938% of the small shareholders' valid votes [8]. Legal Opinion - The legal advisors confirmed that the meeting's procedures, participant qualifications, proposals, voting processes, and results were all in accordance with legal and regulatory requirements [8]. Documents for Reference - The resolutions from the second extraordinary general meeting and the legal opinion from Anhui Chengyi Law Firm are available for review [9].

华兰生物疫苗股份有限公司 2025年第二次临时股东会决议公告 证券代码：301207 证券简称：华兰疫苗 公告编号：2025-043 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、本次股东会的召开时间： 现场会议召开时间为：2025 年 9 月 22 日下午 13:30 网络投票时间：2025 年 9 月 22 日。其中通过深圳证券交易所交易系统进行 网络投票的具体时间为 2025 年 9 月 22 日上午 9:15—9:25,9:30—11:30 和下午 13:00—15:00；通过深圳证券交易所互联网投票的具体时间为 2025 年 9 月 22 日 9:15 至 15:00 期间的任意时间。 2、会议召开地点：华兰生物疫苗股份有限公司（以下简称"公司"）办公楼 会议室 3、召集人：公司董事会 4、会议方式：现场投票、网络投票相结合的方式 通过现场和网络投票的股东 152 人，代表股份 487,150,449 股，占公司有表 决权 ...

关于 华兰生物疫苗股份有限公司 召开 2025 年第二次临时股东会的 法律意见书 安徽承义律师事务所 安徽承义律师事务所 中国.合肥市政务区怀宁路 200 号栢悦中心 5 楼 邮编: 230022 电话（Tel）: （86-551）65609815 传真（Fax）: （86-551）65608051 网址（Website）: www.chengyi-law.com 电子信箱（E-mail）：chengyilawyer@163.com 安徽承义律师事务所 关于华兰生物疫苗股份有限公司 一、本次股东会召集人资格和召集、召开的程序 经核查，本次股东会是由公司第二届董事会召集，公司已于 2025 年 8 月 28 日在中国证监会指定的信息披露网站和深圳证券交易所网站上披露了《关于召开 2025 年第二次临时股东会的通知》。本次股东会的现场会议于 2025 年 9 月 22 日 13:30 在河南省新乡市华兰大道甲 1 号附 1 号公司办公楼会议室如期召开。 本次股东会的召集人资格和召集、召开程序符合法律、法规、规范性文件和 公司章程的规定。 二、本次股东会出席人员的资格 经核查，出席会议的公司股东及股东代表 152 ...

华泰联合证券有限责任公司 关于华兰生物疫苗股份有限公司 2025 年半年度跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：华兰疫苗 | | --- | --- | | 保荐代表人姓名：陈振博 | 联系电话：010-56839300 | | 保荐代表人姓名：刘晓宁 | 联系电话：010-56839300 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但 | | | 不限于防止关联方占用公司资源的制度、募集 | 是 | | 资金管理制度、内控制度、内部审计制度、关 | | | 联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | | ...

Core Viewpoint - The vaccine industry is experiencing a downturn, with significant revenue and profit declines among major companies, attributed to price wars, vaccine hesitancy, and intense competition [4][5][10][20]. Group 1: Industry Performance - In the first half of 2025, the overall vaccine revenue of listed companies in China decreased by 60% year-on-year, and net profit dropped by 113% [5]. - Major vaccine companies like Zhifei Biological and Wantai Biological reported their first half-year losses since going public, with net profits declining by 127% and 155% respectively [5][10]. - Only six out of 17 listed vaccine companies achieved profitability, with the highest profit being 122 million yuan from Chengda Biological [5]. Group 2: Price Wars - The price of flu vaccines has significantly dropped, with some prices reaching as low as 5.5 yuan per dose, leading to a continuous price war in the market [8][9]. - Wantai Biological's revenue from its main product, the bivalent HPV vaccine, fell by 38% to 844 million yuan, marking its first loss since listing [10]. - The price competition has also affected other vaccines, including HPV and shingles vaccines, with prices dropping dramatically in recent years [9][10][11]. Group 3: Vaccine Hesitancy - Vaccine hesitancy has become a significant issue, particularly for non-mandatory vaccines like HPV and flu vaccines, with many individuals expressing doubts about their effectiveness [13][14][15]. - The average flu vaccine coverage in China remains below 4%, significantly lower than in developed countries where it is around 50% [15]. - Factors contributing to vaccine hesitancy include dissatisfaction with COVID-19 vaccine outcomes, misinformation, and a lack of awareness regarding adult vaccinations [15][16]. Group 4: Future Outlook - Experts predict that the current downturn in the vaccine industry may last for five to ten years, with potential consolidation and elimination of weaker companies [20]. - The industry faces challenges in changing public perception and increasing adult vaccination rates, which are crucial for market expansion [20]. - The competition is expected to remain fierce, with many companies struggling to differentiate their products in a saturated market [19][20].

Core Viewpoint - Hualan Vaccine's stock experienced a decline of 1.24% on September 15, with a trading volume of 37.6 million yuan, indicating potential market volatility and investor sentiment shifts [1]. Financing and Margin Trading - On September 15, Hualan Vaccine had a financing buy-in amount of 4.11 million yuan and a financing repayment of 5.61 million yuan, resulting in a net financing outflow of 1.50 million yuan. The total financing and margin trading balance reached 115 million yuan, which is 1.04% of the circulating market value, indicating a relatively high level compared to the past year [1]. - The company had a margin trading activity on the same day, with 3,200 shares repaid and 400 shares sold short, amounting to a short sale value of 7,336 yuan. The remaining short selling volume was 22,100 shares, with a margin balance of 406,200 yuan, also reflecting a high level compared to the past year [1]. Financial Performance - For the first half of 2025, Hualan Vaccine reported a revenue of 59.96 million yuan, representing a year-on-year growth of 68.77%. However, the net profit attributable to shareholders decreased by 17.71% to 20.80 million yuan [2]. - Since its A-share listing, Hualan Vaccine has distributed a total of 680 million yuan in dividends, with 600 million yuan distributed over the past three years [3]. Shareholder Structure - As of August 10, the number of Hualan Vaccine shareholders decreased by 5.26% to 18,000, while the average circulating shares per person increased by 5.56% to 7,869 shares [2]. - As of June 30, 2025, the top ten circulating shareholders included various ETFs and investment funds, with notable changes in holdings among major shareholders, indicating shifts in institutional investment [3].

Group 1 - The core point of the news is that Hualan Vaccine (301207) has seen a net financing purchase of 206.26 million yuan on September 11, 2025, with a financing balance of 1.19 billion yuan, indicating a positive trend in investor sentiment [1][4]. - Over the past three trading days, Hualan Vaccine has recorded a cumulative net purchase of 507.96 million yuan, with 11 out of the last 20 trading days showing net financing purchases [1][4]. - The financing balance increased by 1.76% compared to the previous day, reflecting a growing interest in the stock [4]. Group 2 - On September 11, 2025, there was a net short selling of 100 shares, with a total short selling balance of 2.44 million shares [3]. - In the last 20 trading days, there have been 12 days of net short selling, indicating a bearish sentiment among some investors [3]. - The total short selling balance on September 11 was valued at 45.84 million yuan [3]. Group 3 - The financing and securities lending balance reached 1.20 billion yuan on September 11, 2025, showing a significant increase in trading activity [4]. - The financing balance on September 10 was 1.18 billion yuan, which had increased from 1.16 billion yuan on September 9 [4]. - The fluctuations in the financing balance over the past few days indicate varying investor confidence in Hualan Vaccine [4].

Core Insights - The vaccine industry is experiencing significant challenges, with many companies reporting substantial losses and declining revenues in 2025 [4][20][21] - Price wars and vaccine hesitancy are identified as major factors contributing to the industry's downturn [4][12][14] Financial Performance - In the first half of 2025, major vaccine companies like Zhifei Biological and Wantai Biological reported their first-ever half-year losses, with net profits dropping by 127% and 155% respectively [4][5] - Overall, vaccine revenue for listed companies in China decreased by 60% year-on-year, with net profits down by 113% [4] - Among 17 listed vaccine companies, only 6 reported profits, with the highest profit being 1.22 billion yuan from Chengda Biological [4] Market Dynamics - The top five vaccine companies by market capitalization are Wantai Biological, Zhifei Biological, CanSino, Kangtai Biological, and Watson Biological, with only CanSino showing a profit increase due to its innovative four-valent meningococcal vaccine [4][5] - A significant price drop in flu vaccines has been noted, with prices falling to as low as 5.5 yuan per dose, leading to intense competition [6][7][8] Price Wars - The price of various vaccines, including flu and HPV vaccines, has been driven down due to aggressive competition, with some prices dropping to a fraction of their previous levels [9][10][11] - Wantai Biological's entry into the nine-valent HPV vaccine market has intensified competition, leading to significant price reductions across the sector [9][10] Vaccine Hesitancy - Vaccine hesitancy has become a critical issue, particularly for non-mandatory vaccines, with many individuals expressing doubts about vaccine efficacy [14][15][16] - The overall vaccination rates for flu vaccines remain low in China, with annual rates below 4%, compared to over 50% in developed countries [16] Industry Outlook - The vaccine industry is facing a prolonged period of challenges, with experts predicting that the current downturn may last five to ten years unless significant changes occur in public perception and market dynamics [20][21] - The industry is expected to undergo consolidation, with weaker companies likely to be eliminated as competition intensifies [21]

Core Viewpoint - The vaccine industry in China is experiencing significant challenges, with many companies reporting substantial losses and a decline in revenue due to price wars, vaccine hesitancy, and intense competition [1][4][15]. Group 1: Financial Performance of Vaccine Companies - In the first half of 2025, major vaccine companies like Zhifei Biological and Wantai Biological reported their first-ever half-year losses, with net profits dropping by 127% and 155% respectively [1][3]. - Overall, the revenue of Chinese vaccine listed companies decreased by 60% year-on-year, and net profits fell by 113% in the first half of 2025 [1]. - Among the top five vaccine companies by market capitalization, only CanSino reported a year-on-year net profit increase, attributed to its innovative four-valent meningococcal vaccine [2][3]. Group 2: Price Wars and Market Dynamics - The price of flu vaccines has significantly dropped, with some prices reaching as low as 5.5 yuan per dose, leading to a price war that has affected various vaccine types including HPV and pneumonia vaccines [4][5]. - Wantai Biological's revenue from its main product, the bivalent HPV vaccine, fell by 38% to 8.44 billion yuan, marking its first loss since going public [5][8]. - The industry is facing a normalization of price competition, with companies engaging in various promotional strategies to capture market share, further compressing product pricing [8][15]. Group 3: Vaccine Hesitancy - Vaccine hesitancy has become a significant issue, with many individuals expressing doubts about vaccine efficacy, particularly for non-mandatory vaccines like HPV and flu vaccines [10][12]. - The average flu vaccine coverage in China remains below 4%, significantly lower than in developed countries where it can reach 50% [12]. - Factors contributing to vaccine hesitancy include dissatisfaction with COVID-19 vaccine outcomes, misinformation, and a lack of awareness regarding the importance of adult vaccinations [12][13]. Group 4: Future Outlook and Industry Challenges - The vaccine industry is expected to face prolonged challenges, with experts predicting that the current competitive landscape will lead to consolidation and potential elimination of weaker players [15][16]. - The market for adult vaccines is particularly underdeveloped, and significant efforts are needed to improve public awareness and acceptance [12][16]. - The industry consensus suggests that without substantial changes in public perception and a more robust adult vaccination framework, the market will continue to struggle [16].